HR20013 for the Prevention of Nausea and Vomiting in Patients With Cancer: A Real-World Study

Study acronym: HR20013-RWS
StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
HR20013 is a newly approved medicine in China to prevent nausea and vomiting from anticancer treatment. This prospective, observational, multicenter real-world study will enroll about 3,000 patients receiving this medicine as routine care at over 30 hospitals in China, including 100 with mild to moderate hepatic impairment. Following usual clinical practice, it will evaluate how well the medicine prevents nausea and vomiting and its safety to guide clinical use.
Trial Details
NCT Number NCT07874308
Lead Sponsor Sun Yat-sen University
Conditions
(from sponsor)		 Chemotherapy-Induced Nausea and Vomiting (CINV), Nausea, Vomiting, Neoplasms
Related terms Nausea, Neoplasms, Vomiting
Enrollment 3,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov